167 related articles for article (PubMed ID: 9152970)
41. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
42. Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).
Van Hoef ME; Radford JA; Jones A; Smith IE; Earl HM; Woll PJ; Thatcher N
Ann Oncol; 1993 Dec; 4(10):877-81. PubMed ID: 8117608
[TBL] [Abstract][Full Text] [Related]
43. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
Hastürk S; Kurt B; Kocabas A; Orüç O; Burgut R
J Chemother; 1997 Feb; 9(1):66-71. PubMed ID: 9106021
[TBL] [Abstract][Full Text] [Related]
44. Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease.
Gulati S; Bennett C; Toia M; Gopal A; Gopal R
Anticancer Drugs; 1993 May; 4 Suppl 1():13-6. PubMed ID: 8347851
[TBL] [Abstract][Full Text] [Related]
45. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
[TBL] [Abstract][Full Text] [Related]
46. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
47. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
48. [Use of rHu GM-CSF (Leucomax) in treatment of neutropenia during intensive chemotherapy for acute lymphoblastic leukemia].
Rokicka-Milewska R; Derulska D; Pawelec K
Acta Haematol Pol; 1994; 25(2):111-8. PubMed ID: 8067182
[TBL] [Abstract][Full Text] [Related]
49. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
[TBL] [Abstract][Full Text] [Related]
50. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
[TBL] [Abstract][Full Text] [Related]
51. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Glisson BS; Kurie JM; Perez-Soler R; Fox NJ; Murphy WK; Fossella FV; Lee JS; Ross MB; Nyberg DA; Pisters KM; Shin DM; Hong WK
J Clin Oncol; 1999 Aug; 17(8):2309-15. PubMed ID: 10561292
[TBL] [Abstract][Full Text] [Related]
52. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
53. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
55. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.
Negoro S; Masuda N; Furuse K; Saijo N; Fukuoka M
Cancer Chemother Pharmacol; 1997; 40 Suppl():S70-3. PubMed ID: 9272138
[TBL] [Abstract][Full Text] [Related]
56. Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor.
Gurney H; Anderson H; Radford J; Potter MR; Swindell R; Steward W; Kamthan A; Chang J; Weiner J; Thatcher N
Eur J Cancer; 1992; 28(1):105-12. PubMed ID: 1314626
[TBL] [Abstract][Full Text] [Related]
57. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y; Ohe Y
Eur J Cancer; 1994; 30A(2):188-94. PubMed ID: 7512356
[TBL] [Abstract][Full Text] [Related]
58. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.
Wexler LH; Weaver-McClure L; Steinberg SM; Jacobson J; Jarosinski P; Avila N; Pizzo PA; Horowitz ME
J Clin Oncol; 1996 Mar; 14(3):901-10. PubMed ID: 8622038
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
60. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
